Open Access

Elevated expression of Nrf2 mediates multidrug resistance in CD133+ head and neck squamous cell carcinoma stem cells

  • Authors:
    • Bao‑Cai Lu
    • Jing Li
    • Wen‑Fa Yu
    • Guo‑Zheng Zhang
    • Hui‑Min Wang
    • Hui‑Min Ma
  • View Affiliations

  • Published online on: October 17, 2016     https://doi.org/10.3892/ol.2016.5269
  • Pages: 4333-4338
  • Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Enhanced expression of the ATP-binding cassette (ABC) transporter protein ABC sub-family G member 2 (ABCG2) in cancer stem cells (CSCs) plays a major role in chemotherapeutic drug efflux, which results in therapy failure and tumor relapse. In addition to downregulating apoptosis in CSCs, it has been reported that the transcriptional upregulation of the redox sensing factor Nrf2 is involved in the upregulation of ABCG2 expression and consequent chemoresistance. The current study investigated the presence of cancer stem‑like side population (SP) cells from head and neck squamous cell carcinoma (HNSCC) samples, and evaluated the Nrf2 expression profile and multidrug resistance properties of HNSCC stem cells. Fluorescence‑activated cell sorting was used for SP cells detection, while reverse transcription‑polymerase chain reaction was used for the analysis of Nrf2 expression. The present study identified ~2.1% SP cells present in HNSCC specimens, which were positive for cluster of differentiation (CD)133 expression and displayed significantly elevated messenger RNA expression of Nrf2, compared with non‑SP cells. These data suggest that the ABC transporter ABCG2 is highly upregulated in SP cells, and this results in multidrug resistance. In addition, these CD133+ cells underwent rapid proliferation and exhibited high self‑renewal and tumorigenic properties. Taken together, the present findings suggest that elevated expression of Nrf2 mediated drug resistance in HNSCC CSCs, which may be one of the causative factors for cancer treatment failure. Therefore, novel anti‑cancer drugs that downregulate the Nrf2 signaling pathway could effectively improve the treatment and survival rate of patients with HNSCC.
View Figures
View References

Related Articles

Journal Cover

December-2016
Volume 12 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lu BC, Li J, Yu WF, Zhang GZ, Wang HM and Ma HM: Elevated expression of Nrf2 mediates multidrug resistance in CD133+ head and neck squamous cell carcinoma stem cells. Oncol Lett 12: 4333-4338, 2016
APA
Lu, B., Li, J., Yu, W., Zhang, G., Wang, H., & Ma, H. (2016). Elevated expression of Nrf2 mediates multidrug resistance in CD133+ head and neck squamous cell carcinoma stem cells. Oncology Letters, 12, 4333-4338. https://doi.org/10.3892/ol.2016.5269
MLA
Lu, B., Li, J., Yu, W., Zhang, G., Wang, H., Ma, H."Elevated expression of Nrf2 mediates multidrug resistance in CD133+ head and neck squamous cell carcinoma stem cells". Oncology Letters 12.6 (2016): 4333-4338.
Chicago
Lu, B., Li, J., Yu, W., Zhang, G., Wang, H., Ma, H."Elevated expression of Nrf2 mediates multidrug resistance in CD133+ head and neck squamous cell carcinoma stem cells". Oncology Letters 12, no. 6 (2016): 4333-4338. https://doi.org/10.3892/ol.2016.5269